CART– tag –
-
The Full Picture of CAR-T: A Beginner-to-Expert Series Overview (8 Modules That Trace the Field)
This article serves as the complete index page for the CAR-T series now that the series has been completed. This article serves as the complete index page for the CAR-T series now that the series has been completed. What you will learn W... -
Where CAR-T’s Winning Commercialization Strategy Lies: 4 Implementation Axes — COGS, Supply Chain, Site, Regulation | Frontier of Therapy Series | CAR-T B6 [Expert]
In A5 and B5, we explored how in vivo CAR-T is emerging not simply as a novel scientific idea, but as a possible answer to the structural problems of manufacturing, logistics, and access. In A5 and B5, we explored how in vivo CAR-T is em... -
Why Is CAR-T So Expensive? Reading 3 Cost Drivers in Manufacturing & Access — and the Future Reshaped by Next-Gen Tech | Frontier of Therapy Series | CAR-T A6 [Beginner]
CAR-T therapy is one of the cancer treatments that has attracted particularly strong expectations in recent years. CAR-T therapy is one of the cancer treatments that has attracted particularly strong expectations in recent years. In fact... -
Where In Vivo CAR’s Hardest Problems Live: 4 Implementation Axes — Delivery, Control, Safety, CMC/Reg | Frontier of Therapy Series | CAR-T B5 [Expert]
If you want the beginner version first:→ A5: What is in vivo CAR? If you want the beginner version first:→ A5: What is in vivo CAR? “Making CAR cells inside the body” explained simply What you will learn Executive summary1) Delivery: the... -
What Is In Vivo CAR? Reading the Next-Gen Approach of Making CAR Cells Inside the Body Through 3 Mechanisms | Frontier of Therapy Series | CAR-T A5 [Beginner]
Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index→ A4: Why CAR-T Is Expanding Beyond Cancer (Autoimmunity as an Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index... -
Where Autoimmune CAR-T Is Heading: Design Logic of CD19, BCMA, mRNA CAR and 4 Axes of Company Activity | Frontier of Therapy Series | CAR-T B4 [Expert]
Prefer the overview first?→ A4: Why CAR-T expands beyond cancer (autoimmunity as “reset”) Prefer the overview first?→ A4: Why CAR-T expands beyond cancer (autoimmunity as “reset”) What you will learn Executive summary1) The coordinate sy... -
Why CAR-T Is Expanding Beyond Cancer: Reading 3 Logics of Autoimmune Reset from First Principles | Frontier of Therapy Series | CAR-T A4 [Beginner]
New here?→ A0: What is CAR-T therapy? The big picture + index New here?→ A0: What is CAR-T therapy? The big picture + index What you will learn The short answer: the appeal is “reset,” not chronic suppression1) What “autoimmunity” means ... -
Where Solid-Tumor CAR-T Is Heading: 4 Breakthrough Axes — Multi-Target, Logic Gates, Armoring, and Local Delivery | Frontier of Therapy Series | CAR-T B3 [Expert]
Prefer the beginner overview first?→ A3: Why solid tumors are hard for CAR-T (the 3 barriers) Prefer the beginner overview first?→ A3: Why solid tumors are hard for CAR-T (the 3 barriers) What you will learn Executive summary1) The core ... -
Why Solid Tumors Are Hard for CAR-T: Reading the 3 Barriers That Define Today’s Clinical Bottleneck | Frontier of Therapy Series | CAR-T A3 [Beginner]
New here?→ A0: What is CAR-T therapy? The big picture + index→ A1: Where CAR-T is used today (blood cancers first) New here?→ A0: What is CAR-T therapy? The big picture + index→ A1: Where CAR-T is used today (blood cancers first) What yo... -
Current Standing of CAR-T Toxicity Management: 5 Implementation Challenges Across Site Ops, Long-Term Safety, and Regulation | Frontier of Therapy Series | CAR-T B2 [Expert]
Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + index→ A2: CAR-T side effects without panic (what happens, what to m Prefer the beginner overview first?→ A0: What is CAR-T therapy? The big picture + inde... -
How to Read CAR-T Side Effects: A 3-Axis Map of CRS, ICANS, and Cytopenia for Patients Without Panic | Frontier of Therapy Series | CAR-T A2 [Beginner]
New here? Start with the basics and where CAR-T is used today.→ A0: What Is CAR-T Therapy? The Big Picture + Series Index→ A1: Where CAR-T Is Used Tod New here? Start with the basics and where CAR-T is used today.→ A0: What Is CAR-T Ther... -
FDA-Approved CAR-T Landscape: 7 Products and the Label Logic Behind Their Indications
Eleven CAR-T products have earned FDA approval, each targeting a specific cell, antigen, and disease. A single well-made table is worth a month of white papers—here is how to read it, and where the next approvals will land. Prefer the be... -
Where CAR-T Is Used Today: Reading the Indication Map Through 5 Blood Cancers and Today’s Standing | Frontier of Therapy Series | CAR-T A1 [Beginner]
New here? If you haven’t read the introduction, it will make this post much easier to follow.→ A0: What Is CAR-T Therapy? The Big Picture + Series Ind New here? If you haven’t read the introduction, it will make this post much easier to ... -
CAR-T at a Glance: A Beginner’s Map of Cells, Targets, and Why It Works
How to use this series (two-layer linkage: Beginner → Expert) This series explains CAR-T therapy in a stepwise way so that readers who are new to the term can first grasp the big picture (Layer A), and then move This series explains CAR-... -
Top 10 Global Biotech & Pharma News of 2025 (Ranked #5–#1) — Obesity, ADCs, China Licensing, and M&A Redrew the Map
The second half of 2025’s “top 10” is where the industry’s center of gravity moved. The second half of 2025’s “top 10” is where the industry’s center of gravity moved. The defining themes were clear: obesity drugs entering a second act (... -
Top 10 Global Biotech & Pharma News of 2025 (Ranked #10–#6) — The Year “Policy, Safety, and Supply” Decided Winners
In 2025, innovation alone was not enough. In 2025, innovation alone was not enough. Across biotech and pharma, policy, safety, manufacturing reliability, and reimbursement increasingly determined whether breakthroughs could scale in the ... -
Big Pharma Mega Deals in the Last Few Months Series Part 2 | Next-Generation Oncology: in vivo CAR-T, ADCs, Bispecifics and Oral Biologics
Among the many big pharma transactions announced in the last few months, oncology stands out as the area where activity is both dense and conceptually rich. Among the many big pharma transactions announced in the last few months, oncolog... -
News Watch: in vivo CAR-T RACE (2025 Global Update)
Last updated: 2025-09-01 JST What you will learn Three-Line SummaryWhy in vivo (now)?Company Highlights (Q3 2025)Two Paths, One GoalClinical KPIs to Watch Lead: The shift from ex vivo to in vivo CAR-T is turning into a full-blown race. B... -
Pancreatic Cancer’s “Two Shots on Goal”: Reading 3 Strategic Bets That Could Break the Survival Plateau
Introduction: Why Pancreatic Cancer Is So Difficult to Treat Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a dismal 5-year survival rate of about 10%. Three major challenges underlie this poor ... -
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Comprehensive Summary and Future Outlook
Trilogy Subtitles＋Series Summary Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generatio...
12